This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed l…

Prostate CancerOligometastasisOligorecurrence+3 more

~Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT04787744

Phase 2

Phase II Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.

Prostate Cancer (Adenocarcinoma)Metastatic Prostate Cancer

~Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06616597

← PreviousPage 4 of 4Next →